Full Breakdown
GE HealthCare Moves to Own U.S. Radiopharmaceutical Supply Chain with $945 Million SOFIE Biosciences Deal
By Drooid · · How we work
Core Event
GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences, a U.S. contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, for $945 million in cash. The transaction is slated to close in the first half of 2027, pending customary closing conditions and regulatory approvals. Upon completion, SOFIE will become part of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment.
Background & Context
SOFIE operates 15 U.S. sites with 21 cyclotrons and a theranostics-focused CDMO facility. Its portfolio includes the Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI-74) radiotracer, for which GE HealthCare already holds rights outside the U.S. The acquisition expands GE HealthCare’s “final-mile” PET radiopharmaceutical supply, improving patient access to existing and pipeline products.
Official Statements & Responses
Kevin O’Neill, President & CEO of GE HealthCare’s PDx segment, said the purchase positions the company to grow in the low double-digit range and to serve demand across the radiopharmaceutical value chain. Patrick Phelps, co-founder and CEO of SOFIE, called the deal an “exciting step” that will enable the company to meet rising demand for F18 products.
Analyst Reactions & Price Targets
- Needham reiterated a Buy rating with a $93 target, citing expected revenue and EPS accretion in the first full year post-close.
- RBC Capital maintained an Outperform rating with an $80 target, viewing the deal as consistent with GE HealthCare’s capital-allocation strategy and mid-single-digit long-range growth plan (4 %–6 %).
- Mizuho raised its target to $85, noting an 11 % organic order growth in the most recent quarter.
- Oppenheimer kept an Outperform rating with an $85 target.
- BTIG lifted its target to $79 while keeping a Buy rating, referencing strong Q2 results and recent FDA clearance for the Photonova Spectra CT system.
Data & Statistics
- Acquisition price: $945 million cash.
- SOFIE network: 15 U.S. sites, 21 cyclotrons, CDMO facility for theranostics.
- GE HealthCare Q2 2026 results: Revenue $5.295 billion (3.5 % organic YoY growth), adjusted EPS $1.13, both above consensus estimates.
- Market position: GE HealthCare’s PDx segment supports roughly 140 million imaging procedures projected for 2025, about four procedures per second.
Why It Matters
The acquisition vertically integrates GE HealthCare’s radiopharmaceutical manufacturing, allowing tighter control over supply reliability and faster rollout of tracers such as FAPI-74. Adding a robust CMO network strengthens GE HealthCare’s position in the growing PET radiotracer market, which now has about 20 tracers and over 30 radiotherapeutics in development, and aligns with its end-to-end precision-medicine strategy.
Timeline
- Announcement of acquisition: (date disclosed in company release, no specific calendar date provided).
- Projected closing: First half of 2027, subject to regulatory approvals.
- Q2 2026 earnings release: (referenced in earnings release dated July 29 2026 for non-GAAP definitions).
What’s Next
GE HealthCare will seek regulatory clearance while preparing to integrate SOFIE’s manufacturing capabilities. The company expects the deal to be revenue- and earnings-accretive in the first full year after closing, supporting its mid-single-digit growth outlook. Analysts will monitor integration progress and any updates to long-range financial guidance.